Abstract
Missing heritability in hereditary diffuse gastric cancer (HDGC) ranges from 60 to 90%. These HDGC-like families, despite complying with HDGC clinical criteria, lack CDH1 and CTNNA1 actionable germline variants, and are not offered HDGC-targeted life-saving disease prevention measures. Herein, we explored novel HDGC predisposition mechanisms affecting the CDH1-regulatory network. We called single-nucleotide (SNV) and copy-number variants (CNV) from 19 HDGC-like probands from whole-genome sequencing data and performed gene-ontology analysis. Chromatin enhancer marks and CDH1 promoter interactions were evaluated in normal stomach by ChIP-seq, ATAC-seq and 4C-seq, variant causality was assessed by RT-PCR, immunohistochemistry and microsatellite instability (MSI) analysis in tumours. Functional analysis was performed using CRISPR-Cas9, RT-PCR and flow cytometry in cell lines, and enhancer assays using mouse embryos. Within the CDH1 topologically associating domain (TAD), we found two deletions in Family F4 and F9. F4 carried a heterozygous CDH3 20kb-CNV triggering CDH1 mRNA/protein loss in homozygosity by CRISPR-Cas9 editing, similarly to a CDH1 coding deletion. This 20kb sequence encloses two hypomorphic tissue-specific regulatory elements (REs), each contributing 50% to CDH1 expression regulation. F9 carried a heterozygous 39bp-intergenic CNV downstream of CDH1, triggering CDH1 mRNA/protein loss by CRISPR-Cas9. F15, presenting gastric but not colorectal cancer, carried an MLH1 heterozygous 2.7Kb germline CNV overlapping a stomach-specific RE found by ChIP-seq. The gastric tumour of mixed histology displayed Microsatellite instability (MSI), reduced MLH1 mRNA and protein, and reduced CDH1 and E-cadherin protein. CRISPR-Cas9 clones mimicking the MLH1 heterozygous CNV, triggered loss of MLH1 and CDH1/E-cadherin mRNA and protein, similar to a coding deletion. Beyond the CDH1 TAD and tumour risk syndrome genes, multiple deletions of stomach accessible chromatin sequences were found in particularly young-affected individuals from additional 6 families. This oligogenic pattern impaired specifically mucin genes and multiple immune-related pathways. Herein, we pinpointed novel mechanisms behind HDGC predisposition. One involves deletions of CDH1-REs in the TAD or stomach-specific CDH1-REs in the MLH1 locus. The second involves multiple deletions of stomach REs affecting mucin and immune-related genes, favouring a gastric immune-deficient phenotype. Altogether, by combining stomach-specific chromatin accessibility and promoter interactions with whole genome sequencing, we solved the missing heritability in 47% of HDGC-like families within our cohort.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work received funding from: (1) the European Union Horizon 2020 research and innovation programme under grant agreement No 779257 (Solve‐RD: H2020-SC1-2017-Single-Stage-RTD); (2) The European Regional Development Fund (ERDF) through the COMPETE 2020-Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through Fundacao para a Ciencia e Tecnologia (FCT)(3DChroMe: PTDC/BTM-TEC/30164/2017, LEGOH: PTDC/BTM-TEC/6706/2020, DGCoding: 2023.11994.PEX); (3) FCT with salary support for PhD studentships to CSJ (Ref. SFRH/BD/140796/2018), MF (Ref. 2020.05763.BD) and SL (Ref. 2020.05773.BD). Further, this study has received funding from the European Union Horizon Europe Coordination and Support action under the Grant Agreement 101095483 (PREVENTABLE) for salary support to CSJ.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of centro hospitalar Universitario de Sao Joao gave ethical approval for this work (ethics approval number 445-20 and 305-19).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.